Differentiation of high risk prostate cancer with a facile urinary exosome detection workflow
Summary: Clear differentiation of high-grade and clinically insignificant prostate cancer (PCa) is critical for clinical decision-making. Here, we developed a proprietary urinary exosome isolation approach (EVLatch) and established a facile diagnostic workflow. We discovered that EEF1A1 levels, abun...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004225001567 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206913731657728 |
|---|---|
| author | Shuai Qiu Yue Li Zheng Zhang Chunchang Li Haoyu Wang Ao Chen Zhi Yan Yang Liu Zifei Li Hua Huang Yi Liu Yiqi Seow Ruibing Chen Jinhong Guo Simeng Wen Jing Tian Hongtuan Zhang Ranlu Liu Gang Han Baolong Wang Yong Wang Yuanjie Niu HaiFang Yin |
| author_facet | Shuai Qiu Yue Li Zheng Zhang Chunchang Li Haoyu Wang Ao Chen Zhi Yan Yang Liu Zifei Li Hua Huang Yi Liu Yiqi Seow Ruibing Chen Jinhong Guo Simeng Wen Jing Tian Hongtuan Zhang Ranlu Liu Gang Han Baolong Wang Yong Wang Yuanjie Niu HaiFang Yin |
| author_sort | Shuai Qiu |
| collection | DOAJ |
| description | Summary: Clear differentiation of high-grade and clinically insignificant prostate cancer (PCa) is critical for clinical decision-making. Here, we developed a proprietary urinary exosome isolation approach (EVLatch) and established a facile diagnostic workflow. We discovered that EEF1A1 levels, abundantly expressed on urinary exosomes, positively correlate to urinary exosome counts irrespective of source and collection time and demonstrated that EEF1A1 enables in-assay quantification of urinary exosomes. Importantly, a prostate cancer urinary EVLatch-based artificial intelligence diagnostics (PURE-AID) classification system utilizing PCA3, HOXC6, and DLX1 as targets with SPDEF for reference and EEF1A1 for quality checking, trained on 271 patients, achieved an area under the receiver operating characteristic curve (AUROC) of 0.76 in the test set of 351 patients. Combination of PURE-AID with prostate-specific antigen (PSA) and age increases AUROC to 0.80 and reduces 54.3% of unnecessary biopsies with 86.8% sensitivity. Our study provides a new classification system for differentiating high-grade PCa in a workflow- and patient-friendly manner. |
| format | Article |
| id | doaj-art-ef90c50981d2420f9d391f3e0405633b |
| institution | Kabale University |
| issn | 2589-0042 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj-art-ef90c50981d2420f9d391f3e0405633b2025-02-07T04:48:05ZengElsevieriScience2589-00422025-02-01282111896Differentiation of high risk prostate cancer with a facile urinary exosome detection workflowShuai Qiu0Yue Li1Zheng Zhang2Chunchang Li3Haoyu Wang4Ao Chen5Zhi Yan6Yang Liu7Zifei Li8Hua Huang9Yi Liu10Yiqi Seow11Ruibing Chen12Jinhong Guo13Simeng Wen14Jing Tian15Hongtuan Zhang16Ranlu Liu17Gang Han18Baolong Wang19Yong Wang20Yuanjie Niu21HaiFang Yin22State Key Laboratory of Experimental Hematology & The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, ChinaState Key Laboratory of Experimental Hematology & The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, ChinaDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, ChinaDepartment of Urology, Tianjin Medical University General Hospital, Tianjin 300052, ChinaDepartment of Urology, Tianjin Medical University General Hospital, Tianjin 300052, ChinaState Key Laboratory of Experimental Hematology & The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, ChinaState Key Laboratory of Experimental Hematology & The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, ChinaDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, ChinaDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, ChinaDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, ChinaSchool of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, ChinaGenome Institute of Singapore (GIS), Agency for Science, Technology and Research (A∗STAR), Singapore 138673, Republic of Singapore; Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A∗STAR), Singapore 138673, Republic of SingaporeSchool of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, ChinaSchool of Sensing Science and Engineering, Shanghai Jiao Tong University, Shanghai 200240, ChinaDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, ChinaDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, ChinaDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, ChinaDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, ChinaState Key Laboratory of Experimental Hematology & The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China; Corresponding authorDepartment of Urology, Tianjin Medical University General Hospital, Tianjin 300052, China; Corresponding authorDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China; Corresponding authorDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China; Corresponding authorState Key Laboratory of Experimental Hematology & The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China; China Department of Clinical Laboratory, Tianjin Medical University General Hospital, Tianjin 300052, China; Corresponding authorSummary: Clear differentiation of high-grade and clinically insignificant prostate cancer (PCa) is critical for clinical decision-making. Here, we developed a proprietary urinary exosome isolation approach (EVLatch) and established a facile diagnostic workflow. We discovered that EEF1A1 levels, abundantly expressed on urinary exosomes, positively correlate to urinary exosome counts irrespective of source and collection time and demonstrated that EEF1A1 enables in-assay quantification of urinary exosomes. Importantly, a prostate cancer urinary EVLatch-based artificial intelligence diagnostics (PURE-AID) classification system utilizing PCA3, HOXC6, and DLX1 as targets with SPDEF for reference and EEF1A1 for quality checking, trained on 271 patients, achieved an area under the receiver operating characteristic curve (AUROC) of 0.76 in the test set of 351 patients. Combination of PURE-AID with prostate-specific antigen (PSA) and age increases AUROC to 0.80 and reduces 54.3% of unnecessary biopsies with 86.8% sensitivity. Our study provides a new classification system for differentiating high-grade PCa in a workflow- and patient-friendly manner.http://www.sciencedirect.com/science/article/pii/S2589004225001567Natural sciencesBiological sciencesNeuroscienceCellular neuroscienceTechniques in neuroscience |
| spellingShingle | Shuai Qiu Yue Li Zheng Zhang Chunchang Li Haoyu Wang Ao Chen Zhi Yan Yang Liu Zifei Li Hua Huang Yi Liu Yiqi Seow Ruibing Chen Jinhong Guo Simeng Wen Jing Tian Hongtuan Zhang Ranlu Liu Gang Han Baolong Wang Yong Wang Yuanjie Niu HaiFang Yin Differentiation of high risk prostate cancer with a facile urinary exosome detection workflow iScience Natural sciences Biological sciences Neuroscience Cellular neuroscience Techniques in neuroscience |
| title | Differentiation of high risk prostate cancer with a facile urinary exosome detection workflow |
| title_full | Differentiation of high risk prostate cancer with a facile urinary exosome detection workflow |
| title_fullStr | Differentiation of high risk prostate cancer with a facile urinary exosome detection workflow |
| title_full_unstemmed | Differentiation of high risk prostate cancer with a facile urinary exosome detection workflow |
| title_short | Differentiation of high risk prostate cancer with a facile urinary exosome detection workflow |
| title_sort | differentiation of high risk prostate cancer with a facile urinary exosome detection workflow |
| topic | Natural sciences Biological sciences Neuroscience Cellular neuroscience Techniques in neuroscience |
| url | http://www.sciencedirect.com/science/article/pii/S2589004225001567 |
| work_keys_str_mv | AT shuaiqiu differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT yueli differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT zhengzhang differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT chunchangli differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT haoyuwang differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT aochen differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT zhiyan differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT yangliu differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT zifeili differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT huahuang differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT yiliu differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT yiqiseow differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT ruibingchen differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT jinhongguo differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT simengwen differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT jingtian differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT hongtuanzhang differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT ranluliu differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT ganghan differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT baolongwang differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT yongwang differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT yuanjieniu differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow AT haifangyin differentiationofhighriskprostatecancerwithafacileurinaryexosomedetectionworkflow |